Plain-English translation of NCT07442903 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a tiny wireless sensor called the Cordella PA pressure sensor system can help prevent heart failure hospitalizations in patients with a leaky tricuspid valve (the valve on the right side of your heart). The sensor sits in a blood vessel and continuously monitors pressure in your lungs, sending information to your doctor so they can adjust your heart failure medications before problems develop. Patients in this study will have the sensor implanted before their scheduled tricuspid valve repair procedure.
Even after successful tricuspid valve repair, many patients still end up back in the hospital with worsening heart failure—sometimes within months. This medication has worked well in patients with left-sided heart failure, but doctors don't yet know if it can prevent hospitalizations in right-sided heart failure. This trial will help answer that question.
You likely qualify if…
You likely don't qualify if…
You will have the Cordella heart monitoring sensor implanted before your scheduled tricuspid valve repair procedure. After implantation, you will use a small handheld device at home to transmit your heart pressure readings to your doctor's office regularly—typically daily or several times per week. Your doctor will use this information to guide adjustments to your heart failure medications. You'll have follow-up visits to check how well the system is working and how you're doing overall throughout the study period.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Germany